

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)



GB 99/3133

The
Patent
Office

PCT/GB 99/03133



INVESTOR IN PEOPLE

REC'D 25 OCT 1999

WIPO PCT

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ


**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



P. Mahoney

Signed

Dated 14 October 1999

THIS PAGE BLANK (USPTO)

21 SEP 1998

The
**Patent
Office**

22 SEP 98 E391704-1 D00192
F01/7700 25.00 - 9820555.2

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form))

9820555.2

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference N.75052 - PEJ

2. Patent application number
(The Patent Office will fill in this part)

3. Full name, address and postcode of the or of each applicant (underline all surnames)

ISIS INNOVATION LIMITED
2 SOUTH PARKS ROAD
OXFORD
OX1 3UB

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

03 99 856 4001
UNITED KINGDOM



4. Title of the invention FIBRILS

5. Name of your agent (if you have one) J A KEMP & CO

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

14 SOUTH SQUARE
GRAY'S INN
LONDON WC1R 5LX

Patents ADP number (if you know it)

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country	Priority application number (if you know it)	Date of filing (day / month / year)
---------	---	--

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing (day / month / year)
-------------------------------	--

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer "Yes" if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body:

See note (d))

YES

Patents Form 1/77


9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 23

Claim(s) 5

Abstract 1

Drawing(s) 7 + 7 

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)


Request for preliminary examination and search (Patents Form 9/77) 1

Request for substantive examination (Patents Form 10/77)

Any other documents
(please specify)

11. I/We request the grant of a patent on the basis of this application

Signature



Date 21 September 1998

J A KEMP & CO

12. Name and daytime telephone number of person to contact in the United Kingdom P G A ELLIS-JONES
0171 405 3292

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered "Yes" Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

FIBRILS

The present invention relates to amyloid fibrils, processes for their preparation and their use. The invention in particular relates to both naturally occurring amyloid fibrils and non-naturally occurring amyloid fibrils comprising a protein, their preparation and their use, for example, as a slow-release form of pharmaceutically active proteins, or in the delivery of pharmaceutically active compounds, electronics or catalysis.

The amyloidoses are a group of protein misfolding disorders characterised by the accumulation of insoluble fibrillar protein material in extracellular spaces. The deposition of normally soluble proteins in this insoluble form is believed to lead to tissue malfunction and cell death. A number of different proteins and polypeptides have been identified in amyloid deposits to date. These include the A β peptide in Alzheimer's disease, the prion protein in the transmissible spongiform encephalopathies, the islet-associated polypeptide in type II diabetes, and other variant, truncated, or misprocessed proteins in the systemic amyloidoses (S.Y. Tan and M.B. Pepys (1994) *Histopathology* 25, 403-414 and J.W. Kelly (1996) *Curr. Op. Struct. Biol.* 6, 11-17).

Proteins known to form amyloid fibrils *in vivo*

appear to have no obvious sequence or structural similarities, and where the soluble folds of the amyloidogenic precursors are known they span the range of secondary, tertiary, and quaternary structural elements.

5 In spite of this diversity, there is a body of evidence that indicates that all amyloid fibrils are long, straight and unbranching, with a diameter of from 7 to 12 nm, and they all exhibit a cross- β diffraction pattern. The protein molecules constitute individual or multiple
10 beta-strands oriented perpendicular to the long axis of the fibril and forming long beta-sheets that propagate in the direction of the fibril twisting around each other.

The mechanism by which amyloidogenic proteins undergo the conversion from a soluble globular form to
15 the cross- β conformation displayed by the disease-associated fibrils has not yet been elucidated. Nevertheless, the conformational reorganization associated with amyloid formation is well documented (J.W. Kelly (1997) *Structure* 5, 595-600. Studies of some
20 of the amyloidogenic variants of transthyretin, lysozyme and the Ig light chain have investigated the process of conformational change that leads to amyloid deposition.

Amyloid formation for the latter three proteins appears to start from partially structured forms of the proteins.

25 The present invention concerns naturally occurring amyloid fibrils, which to date have been associated with

disease, and non-naturally occurring amyloid fibrils comprising a protein which may have a variety of useful applications. The fibrils may be used, for example, as a slow-release form of pharmaceutically active proteins, or
5 in the delivery of pharmaceutically active compounds, electronics or catalysis.

In a first aspect, the present invention provides amyloid fibrils substantially free of other protein.

In one embodiment the fibril is an amyloid fibril
10 substantially free of other protein other than an amyloid fibril formed from an SH3 domain of a p85 α subunit of bovine phosphatidylinositol 3-kinase at pH 2.0.

In a further embodiment the fibril is an amyloid fibril substantially free of other protein other than an
15 amyloid fibril formed from an SH3 domain of a p85 α subunit of bovine phosphatidylinositol 3-kinase.

The amyloid fibril may be naturally or non-naturally occurring. The naturally occurring amyloid fibrils of the present invention include, for example a fibril of the A β
20 peptide associated with Alzheimer's disease, the prion protein associated with the transmissible spongiform encephalopathies, the islet-associated polypeptide

associated with type II diabetes, transthyretin and fragments thereof associated with senile systemic
25 amyloidosis, transthyretin variants and fragments thereof associated with familial amyloidotic polyneuropathy or

other variant or truncated or misprocessed proteins associated with systemic amyloidoses.

In a second aspect the present invention provides a non-naturally occurring amyloid fibril comprising a
5 protein.

In one embodiment the fibril is a non-naturally occurring amyloid fibril comprising a protein other than an amyloid fibril formed from an SH3 domain of a p85 α subunit of bovine phosphatidylinositol 3-kinase at pH
10 2.0.

In another embodiment the fibril is a non-naturally occurring amyloid fibril comprising a protein other than an amyloid fibril formed from an SH3 domain of a p85 α subunit of bovine phosphatidylinositol 3-kinase.

15 In a further embodiment the fibril is a non-naturally occurring amyloid fibril comprising an SH3 domain of a p85 α subunit of bovine phosphatidylinositol 3-kinase and at least one protein selected from a derivative or amino acid variant of an SH3 domain of a
20 p85 α subunit of bovine phosphatidylinositol 3-kinase, human muscle acylphosphatase or a derivative or amino
~~acid variant thereof and bovine insulin or a derivative~~
or amino acid variant thereof.

By "protein", as used herein, is meant one or more
25 proteins, protein fragments, polypeptides or peptides.
The protein is any protein capable of forming fibrils and

may be a pharmaceutically active protein.

The fibrils of the present invention may comprise non-naturally occurring proteins. The proteins may be, for example, proteins which have been chemically modified
5 such as proteins which have been glycosylated or proteins which comprise a modified amino acid residue, a pharmaceutically active compound, a metal or a functional group such as a thiol group which is capable of binding one or more reactants. The protein is, for example a
10 derivative or amino acid variant of an SH3 domain (PI3-SH3) of a p85 α subunit of bovine phosphatidylinositol 3-kinase, human muscle acylphosphatase or bovine insulin.

The fibrils of the present invention are typically long, straight and unbranching. The diameter of the
15 fibrils is generally from 1 to 20 nm, preferably from 5 to 15 nm and more preferably from 7 to 12 nm. The diameter of the fibrils may be varied by selecting suitable proteins.

It is believed that the fibrils of the present
20 invention comprise a hollow core which may be useful in a variety of applications.

~~It has been found that the fibrils of the present~~
invention may be obtained by preparing a solution comprising a protein, typically one or more single chain
25 polypeptides, said solution being in a state so that nucleation of the protein and fibril growth will occur

over an acceptable time, and allowing nucleation and fibril growth to take place.

By "nucleation", as herein used, is meant the initiation of processes that lead to fibril formation.

5 Fibril formation from a solution involves, successively, protein self-association, formation of aggregates and fibril growth. Thus, desirably, the initiation solution is on the verge of instability. Nucleation and growth are slow processes and conditions are normally chosen so that
10 fibril formation occurs over a period of hours or days. It will be appreciated that if nucleation occurs too rapidly then this will often have an adverse affect on fibril formation.

Nucleation can be caused by a variety of means
15 including variations in solvents, concentration, salt, ligands, temperature and pH, as discussed below.

The solution comprising a protein may comprise any solvent or mixture of solvents in which nucleation can occur. For example, the solution may comprise DMSO,
20 dioxan and/or water. Preferably the solution is an aqueous solution.

~~One or more organic solvents which can promote~~
nucleation and fibril growth may be incorporated into the solution. In the case of naturally occurring proteins
25 conditions are typically chosen to denature at least partially the protein whilst retaining conditions in

which self-association can occur. The organic solvent is generally water-miscible and is preferably an alcohol.

The alcohol is typically a C₁₋₆ alkanol which may be substituted or unsubstituted for example by one or more

5 halogen atoms, especially fluorine atoms. Examples include methanol, ethanol, propanol or butanol, or fluorinated alcohols such as trifluoroethanol or hexafluoroisopropanol. Preferably the alcohol is trifluoroethanol. The concentration of alcohol is
10 typically from 5 to 40% v/v and preferably about 25% v/v.

The concentration of protein in the solution is not limited in any way but it must be such that nucleation can occur. Generally the concentration is from 0.1 mM to 10 mM. Preferably the concentration of protein is about
15 1mM.

The temperature of the solution is generally from 0°C to 100°C. Preferably the temperature is from 0°C to 70°C, more preferably from 0°C to 40°C and most preferably from 5°C to 30°C.

20 The pH of the solution is any pH suitable for nucleation. Preferably the solution is acidic and more preferably the pH of the solution is from 0.5 to 6.5.

The solution may be seeded with, for example, previously formed particles of protein.

25 The fibrils of the present invention are suitably isolated by centrifugation, filtration or evaporation of

solvent. The fibrils thus obtained may then be washed and dried.

The fibrils of the present invention may be formed from pharmaceutically active proteins such as insulin, calcitonin, angiostatin or fibrinogen. The fibrils may
5 therefore be used as a slow release form of such proteins due to the low solubility of the fibrils *in vivo*.

Alternatively, the fibrils of the present invention may be used in the delivery of pharmaceutically active
10 compounds. They may, for example, comprise a protein which has been chemically modified to incorporate a pharmaceutically active compound or a pharmaceutically active compound may be retained in the hollow core of the fibril by, for example, hydrogen bonding. Pharmaceutically
15 active compounds which may be delivered using the fibrils of the present invention include, for example, cancer drugs such as cis Pt, anti-biotics, anti-inflammatories and analgesics.

The fibrils of the present invention may comprise
20 one or more functional groups capable of binding one or more reactants. The functional groups may occur naturally in the protein of the fibrils or be incorporated by

chemical modification. Reactants may be brought together inside or outside the hollow core of the fibrils.

25 The fibrils of the present invention may be used in the treatment of, for example, diabetes, blood clotting

disorders, cancer and heart disease.

The fibrils of the present invention may comprise a metal, such as copper, silver or gold, and form wires which may be useful in electronics.

5 The present invention is further illustrated, merely by way of example, with reference to the Figures in which:

Figures 1(a) to 1(d) show negative stain electron microscopy images of SH3 amyloids, showing a range of
10 morphologies similar to those observed with disease-related fibrils. Figure 1(e) shows a cryo EM image and (f) shows the diffraction pattern of the form seen in (d) with an obvious helical twist, which was used for 3D reconstruction. The layer line spacing is around 60 nm,
15 the asymmetric unit of the double helix. The various ribbons and smooth fibrils were formed at pH 2 (a,b) and pH 2.66 (c). The helical fibres formed at pH 2 are seen by negative stain in (d) and cryo EM in (e).

Figure 2 shows class averages (a,e), reprojections
20 of 3D reconstructions (b,f), 1D projections (c,g) and diffraction patterns of the reprojections (d,h) for the 58 and 61 nm long repeats, respectively. (In this figure

only, the fibre axis is horizontal). A region in (a) showing a ~3 nm periodicity is enlarged and marked with
25 lines. The good agreement between the input class averages and the reprojections of the 3D maps (compare a

to b and e to f), and also between the diffraction pattern of a single fibril and of reprojected maps (g,h), supports the validity of the reconstruction procedure. The line projection comparisons (c,g) show that the 3D maps fit the input images better when the 2.7 nm subunit repeat is used in the reconstruction procedure than if the fibre is treated as continuous helix.

Figure 3 shows 3D reconstructions and contoured density sections of the 61 nm (a,c) and the 58 nm form (b,d). The fibrils are shown as rendered surfaces in a and c, and as contoured density cross-sections in c and d. The two independent reconstructions are very similar and both show four protofilaments winding around a hollow core, with protruding edge regions. The 2.7 nm subunit repeat is most pronounced on the edge structure.

Figure 4 shows modelling the polypeptide fold in the fibrils. Figure 4 (a) shows a cross-section of the fibre and Figure 4 (b) shows a side view of a single protofilament. β -sheets derived from the PI3-kinase SH3 structure have been fitted into the map, after opening the β sandwich fold and reorientating and strengthening the strands. The remaining regions of polypeptide sequence are shown as disconnected dots, to indicate the number of residues present but not the conformation. At the angle of view in (a), the upper right and lower left protofilaments curve inwards below the plane of view,

making the quality of the fit less apparent. The side view in (b) shows that the β -sheets fit well into the density.

Figure 5A shows a far-UV circular dichroism spectra of muscle acylphosphatase acquired during a fibrillogenesis process. The first and last spectra reported in the figure were acquired after 3 and 600 minutes from the initiation of the reaction, respectively. The spectra show a slow two-state transition between two conformations containing significant amounts of α -helical and β -sheet structure, respectively. After 600 minutes the spectra did not change their shapes but underwent a progressive reduction of signal and a shift of the negative peak towards the higher wavelengths, as a result of the accumulation of protein aggregates of major size. Figure 5B shows an amide I region of the infra-red spectrum of muscle acylphosphatase. The two peaks at 1613 and 1685 cm^{-1} indicate a cross- β structure.

Figures 6A-C are electron micrographs showing the morphological development of the muscle acylphosphatase aggregate. Figure 6A shows an aggregate of granular aspect after 72 minutes from initiation of the reaction. Figure 6B shows short fibrils after 32 hours. Figure 6C shows amyloid fibrils after two weeks. The scale bar represents a distance of 100 nm. Figure 6D shows an

optical microscope photograph of a sample containing muscle acylphosphatase-derived aggregate obtained after two weeks of incubation. The arrows indicate the blots of green birefringence coming from regions of amyloid fibril.

The Examples which follow further illustrate the present invention with reference to the Figures.

Examples

Example 1

Microscopy and image classification

Samples of twisted fibrils of the PI3-kinase SH3 domain formed after several months incubation at pH 2 (J.I. Guizarro et al (1998) *Proc. Natl. Acad. Sci. USA.* 95, 4224-4228) were vitrified on holey carbon grids, and low electron dose images were recorded at 120 kV and 1.3-1.5 μ m underfocus on a JOEL 1200 EX microscope with an Oxford Instruments cryotransfer stage at 30,000x. Films were digitised on a Leafscan 45 linear CCD scanner (Ilford Ltd, Cheshire, UK) at a spacing of 10 μ m, and interpolated to 0.67 nm/pixel for processing. Calculated diffraction patterns (Figure 1f) were obtained by straightening fibres with Phoelix software, but the axial resolution was severely limited in the pitch, which ranged from 54.5 to 66 nm. In order to avoid resolution loss due to non-linear interpolation, digitised fibres

were cut into individual repeats and treated as single particles. 890-cut-out repeats were iteratively aligned and sorted into classes by multivariate statistical analysis, using either Imagic or Spider. This allowed
5 identification of classes of repeats that were naturally straight and had the same length.

3D Reconstruction

Two class averages of with low inter-image variance,
10 containing 92 and 77 images (~20% of the data set), corresponding to a 58 and 61 nm repeat respectively, were selected for 3D reconstruction. The repeat length was determined by cross-correlation of the class averages with the excised cross-over region. The subunit repeat
15 was clearly observable in axial 1D projections of the class averages after square root amplitude filtering (Figure 2c,g). The repeat was determined as approximately 2.7nm in both cases, and the value used was chosen to give an integral number of subunits in the 58 and 61 nm
20 repeats (21 and 22 subunits respectively). 3D reconstructions were calculated by back projection, ~~assuming either a continuous helix or the 27 nm subunit~~
repeat. The overall features of protofilament packing and density cross section were unaffected by imposition of a
25 subunit repeat, but the line projections (Figure 2c,g) and diffraction patterns (Figure 2d,h) of the reprojected

images gave a better match to the input data when the 27 nm repeat was imposed. The diffraction pattern of the reprojected helix gave excellent agreement with the original one from the straightened fibre, and showed strong intensity to 22 nm resolution in the equatorial (radial) direction (Figure 1f). Resolution tests by Fourier shell correlation and phase residual between cross sections of the two maps (Figure 3c,d) show agreement to 2.5 nm, but there is reliable information to 2.2 nm in the equatorial direction for each map. The absolute handedness is not determined by this method and is arbitrary. Other procedures have been used for correlation of the helical disorder based on cross-correlation and back projection. The 3D maps were examined with AVS (Advanced Visualisation System) and β -sheet fitting was done in O.

The native fold of the 84 residue SH3 domain of the p85 α subunit of bovine PI3 kinase contains five β -strands arranged in a β -sandwich. At low pH, the protein partially unfolds and assembles into amyloid fibrils. The images in Figures 1a to 1d show a range of twisted and flat ribbons, and smooth and twisted tubular fibres. For structural analysis, a form with a pronounced helical twist was selected. Diffraction patterns (Figure 1f) calculated from cryo EM images (Figure 1e) contain layers at spacings between 54.5 to 66 nm, the distance between

helical cross-overs in the double-helical structure, ie. the length of the helical repeat.

The diffraction data show structure information to 2.2 nm resolution in the equatorial direction

5 (perpendicular to the fibre axis), but the meridional pattern fades out around 15 nm due to variations in the helical pitch (angular disorder). To retrieve the structural information lost due to angular disorder, the digitised images of the fibrils were divided up into
10 individual helical repeats. These repeats were aligned and sorted into classes according to their length. The class averages of a 28 and a 61 nm repeat are shown in Figure 2 a,e, along with reprojections of 3D maps calculated from these two repeats (2b,f), and their
15 diffraction patterns (2d,h). A subunit repeat is visible in the class average (Figure 2a, expanded) and sometimes in the raw images (not shown). A subunit periodicity of 2.7 ± 0.3 nm projections of the class averages was determined (Figure 2c,g).

20 The two independent 3D maps, derived from the 58 and 61 nm repeats, reveal the same features (figure 3). The ~~surface views and cross sections show two pairs of thin~~
profilaments winding around a hollow core. Regions of weaker density form the extended edges that give the
25 fibrils their characteristic twisting appearance. The profilaments are about 4 nm part and 2 nm thick (Figure

3c,d), too thin to accommodate the native SH3 structure, whose minimum dimension is 3 nm. X-ray fibre diffraction of SH3 amyloid indicates an ordered core of cross- β structure with a 0.47 nm meridional and a 0.94 nm equatorial repeat defining the inter-strand and inter-sheet distances respectively. The 2 nm width can only fit two β -sheets, which must be orientated differently from those in the native fold to make all the strands perpendicular to the fibre axis. The twist between β -strands is also very restricted by the narrow dimension and ling pitch of the protofilaments, giving flat sheets with an inter-strand angle of less than 2° .

A model in which the SH3 are reorganised to fit into the EM density is shown in Figure 4. The remaining short and long loops are the right size range and provide the contracts between adjacent protofilaments and to give rise to diffuse density in the protruding edges of the structure. Consistent with the observation that fibres are seen to split into sub-fibrils, that individual polypeptide chains could contribute β -strands to each member of a pair of protofilaments. Since the axial repeat corresponds to 5 β strands, it is possible that this is related to the 2- and 3-stranded sheets of the native fold by a rearrangement similar to a domain swapping mechanism. Non-covalent interactions would then provide the bonds assembling the adjacent sub-fibrils

into the double helical structure.

The structure determined here, in which the protofilaments are effectively continuous β -sheets, may provide a basic model for all amyloid fibres,

5 irrespective of the chain length and native conformation of the component protein. Indeed, negative stain EM, atomic force microscopy and fibre diffraction of A β (1-40) fibrils suggest a very similar morphology with two sub-

10 fibrils and 3-5 protofilaments. EM studies of ex vivo transthyretin fibrils indicate that these consist of four protofilaments of diameter 5-6 nm. The transthyretin protofilament core has been modelled, based on X-ray fibre diffraction data, as four β -sheets with a 15° twist between adjacent strands. The two-sheet protofilament

15 model presented here could however be extended to a larger number of sheets for thicker protofilaments. At present there is no evidence to discriminate between twisted and flat β -sheets in the larger protofilament type, but the maps are not consistent with as twisted sheet configuration for the SH3 protofilaments since they

20 are only 2 nm thick and have a very small overall twist.

Although flat, untwisted β -sheets are unusual in the protein structure database, part of the β -helix of alkaline protease has such a structure.

25 The cryo-EM work provides 3D information on how a polypeptide chain is assembled into amyloid fibrils.

Polymerisation into fibrils appears to require at least partial unfolding of native proteins and does not appear to be restricted to proteins whose native fold contains β -sheets. Indeed, formation of fibrils from native sheets of proteins is frequently associated with a conversion from helical to sheet structure. Even in the case of the SH3 domain, where the native fold is largely β structure, the structure of the fibrils suggests that this must be substantially rearranged relative to that of the native protein.

Example 2

Example 2 (i)

Muscle acylphosphatase was purified as previously reported (A. Modesti et al. (1995) *Protein Express Purif.* 6, 799) and incubated at a concentration of 0.375 mg/ml (34 μ M) in 25 % v/v trifluoroethanol (TFE), acetate buffer, pH 5.5 at 25 °C under constant stirring. Aliquots were withdrawn at regular time intervals for electron microscopy and spectroscopic analysis. Circular dichroism spectra were acquired directly by means of a Jasco J-720 spectropolarimeter and cuvettes of 1 mm path length.

Electron micrographs were acquired by a JEM 1010 transmission electron microscope at 80 kV excitation voltage. A 3 μ L sample of protein solution was placed and dried for five minutes on a Formvar and carbon-coated

grid. The sample was then stained with 3 μ L 1 % phosphotungstic acid solution and observed at magnifications of 25-100k.

5 Example 2 (ii)

Infrared spectra were acquired using BaF₂ windows of 50 μ m path length.

Example 2 (iii)

10 Thioflavin T and Congo Red assays were performed according to Le Vine III (H. Le Vine III (1995) *Amyloid: Int. J. Exp. Clin. Invest.* 2, 1.) and Klunk (W. E. Klunk et al. (1989) *J. Histochem. Cytochem.* 37, 1293), respectively. For Congo Red birefringence experiments
15 aliquots of protein were air dried onto glass slides. The resulting films were stained with a saturated solution of Congo red and sodium chloride, corrected to pH 10.0 with 1 % sodium hydroxide. The stained slides were examined by an optical microscope between crossed polarizers.

20 There is increasing evidence that amyloids develop not directly from the native and functional conformation of the protein, but from an amyloidogenic precursor
bearing scant resemblance with the conformation of the native protein and identifiable in a denatured
25 conformation containing a certain level of residual structure. This conformation is often referred to as

amyloidogenic intermediate. Muscle acylphosphatase is a protein that adopts, under physiological conditions, a well-defined fold, the stability of which is close to the average value for proteins of this size. Studies

5 performed using trifluoroethanol (TFE) have revealed that muscle acylphosphatase is denatured at concentrations of TFE higher than 20-22% v/v. The denaturation of muscle acylphosphatase by TFE allows the maintenance of native α -helical structure of the protein and is accompanied by
10 a virtual disruption of the hydrophobic core and by the concomitant formation of non-native α -helical structure. Further addition of TFE causes the accumulation of extra α -helical structure and the destabilisation of putative hydrophobic interactions that might be present under the
15 lower alcohol concentrations. Therefore, an aqueous solution containing 25 % v/v TFE, the lowest alcohol concentration at which the native protein is virtually absent, was chosen for fibril formation.

The sequence of events after mixing was probed by a
20 variety of techniques including far-UV circular dichroism (CD), tryptophane intrinsic fluorescence, Congo Red and ~~Thioflavin T binding, electron microscopy and Congo Red~~
birefringence. Following the rapid denaturation of the protein, occurring on a time-scale of seconds, far-UV CD
25 analysis revealed the presence of a slow transition, completed within 2-3 hours, from a conformation rich in

α -helical structure to another containing a considerable content of β -sheet structure (Figure 5A). Far-UV CD spectra were acquired at regular time intervals over this period. The first CD spectrum is typical of a

5 conformation rich in α -helical structure with two negative peaks centred at 208 and 222 nm. This spectrum changes gradually to a β -sheet spectrum with a single negative peak around 216 nm (Figure 5A) The presence of two isodichronic points at 210 and 225 nm suggests that

10 such α/β transition consists of a two-state process. That such β -sheet structure derives from the intermolecular hydrogen bonding established within a protein aggregate is suggested by the two bands at 1685 and 1613 cm^{-1} in the amide region of the infra-red spectrum (Figure 5A)

15 and by the electron micrographs revealing the presence of protein aggregates of granular aspect from samples recovered at this stage of the aggregation process (Figure 6A).

After a period of ca. 32 hours the electron

20 micrographs revealed the presence of short filaments, indicating that a fibrillar protein aggregate had grown

to a significant extent. After two weeks the fibrillar material was more evident. The fibrils revealed by the electron micrographs were long, unbranched and 8.5nm in

25 width, whereas very short filaments or other protein aggregates of granular aspect were no longer present. A

series of optical tests were performed to investigate further the amyloid nature of this fibrillar material. A three fold increase of the 482 nm fluorescence (excitation 440 nm) of the dye Thioflavin T was observed as a consequence of the addition of the protein aggregate, a result expected for amyloids. In addition, the protein aggregate produced a red-shift of the maximum light absorption of the dye Congo Red. The subtraction of the absorption spectra of the aggregate alone and Congo red dye alone from the spectrum containing both the aggregate and the Congo Red dye produces a spectrum, with a maximum intensity at 540 nm. These two findings are also indicative of the presence of amyloid fibrils. Finally, the addition of Congo Red to a sample with muscle acylphosphatase-derived fibrils produced the characteristic green birefringence under cross-polarised light (Figure 6D). The development of green birefringence is highly diagnostic for the presence of amyloid fibrils. In summary, the muscle-acylphosphatase responded positively to all diagnostic tests for the presence of amyloid fibrils.

Recently, amphipathic compounds such as phospholipids have been suggested to facilitate the elongation of the fibrils. The formation of amyloid fibrils by fluoroalcohols like TFE supports this suggestion that such amphipathic compounds normally

present in biologic systems might act as a medium for the growth of amyloid fibrils *in vivo*.

Concentrations of TFE lower than 20 % or higher than 35 % did not lead to fibril formation. This may be because the fibrillogenesis process is hindered by the presence of the native conformation of the protein at low TFE concentrations or by the presence of denatured states too rich in α -helical structure at high concentrations of TFE. These may reduce the concentration of the amyloidogenic precursor acting therefore as kinetic traps for the process of fibril formation. Very high protein concentrations may also constitute an obstacle to the process of the fibrillogenesis process. When incubated at concentrations higher than 3 mg/ml muscle acylphosphatase led to the rapid and irreversible formation of a gel-like precipitate that electron microscopy revealed to be an amorphous protein aggregate. Amyloidogenesis, like crystallogenesis, is a process in which the protein molecules self-assemble to form ordered structures. High protein concentrations may favour the concentrations of molecules and accelerate any aggregation process. Under such conditions, however, there may not be sufficient time for formation of ordered and repetitive conformations.

CLAIMS

1. An amyloid fibril substantially free of other protein.

5

2. A fibril according to claim 1 which is a naturally occurring amyloid fibril.

10

3. A fibril according to claim 2 which comprises the A β peptide associated with Alzheimer's disease, the prion protein associated with the transmissible spongiform encephalopathies, the islet-associated polypeptide associated with type II diabetes, transthyretin and fragments thereof associated with senile systemic amyloidosis, transthyretin variants and fragments thereof associated with familial amyloidotic polyneuropathy or other variant, truncated, or misprocessed proteins associated with the systemic amyloidoses.

20

4. A non-naturally occurring amyloid fibril comprising a protein.
-

25

5. A fibril according to any one of the preceding claims which is not an amyloid fibril formed from an SH3 domain (PI3-SH3) of a p85 α subunit of bovine

phosphatidylinositol 3-kinase at pH 2.0.

6. A fibril according to claim 5 which is not an amyloid fibril formed from an SH3 domain (PI3-SH3) of a p85 α subunit of bovine phosphatidylinositol 3-kinase.

7. A fibril according to any one of claims 4 to 6 wherein the protein is a non-naturally occurring protein.

8. A fibril according to any one of claims 4 to 7 wherein the protein is selected from a derivative or amino acid variant of an SH3 domain (PI3-SH3) of a p85 α subunit of bovine phosphatidylinositol 3-kinase, human muscle acylphosphatase and bovine insulin.

9. A non-naturally occurring amyloid fibril comprising an SH3 domain (PI3-SH3) of a p85 α subunit of bovine phosphatidylinositol 3-kinase and at least one protein selected from human muscle acylphosphatase, bovine insulin and the proteins as defined in claim 8.

10. A fibril according to any one of the preceding

claims which further comprises a pharmaceutically active compound.

11. A fibril according to any one of claims 1 to 9 which
5 further comprises a metal.

12. A fibril according to claim 11 in which the metal is copper, silver or gold.

10 13. A fibril according to any one of claims 1 to 12 which further comprises one or more functional groups capable of binding one or more reactants.

14. A fibril according to any one of claims 1 to 13
15 wherein the diameter of the fibril is from 1 to 20 nm.

15. A fibril according to claim 14 wherein the diameter of the fibril is from 5 to 15 nm.

20

16. A fibril according to claim 15 wherein the diameter
of the fibril is from 7 to 12 nm.

17. A process for preparing a fibril as claimed in any
25 one of the preceding claims which process comprises preparing a solution comprising a protein, said

solution being in a state so that nucleation and fibril growth will occur over an acceptable time, and allowing nucleation and fibril growth to take place.

5

18. A process according to claim 17 wherein the solution further comprises an alcohol.

10

19. A process according to claim 18 wherein the alcohol is selected from methanol, ethanol, propanol, butanol, trifluoroethanol and hexafluoroisopropanol.

15

20. A process according to anyone of claims 17 to 19 wherein the concentration of protein in the solution is from 0.1 mM to 10 mM.

20

21. A process according to any one of claims 17 to 20 wherein the temperature of the solution is from 0°C to 100°C.

22. A process according to any one of claims 17 to 21 wherein the solution is acidic.

25

23. A process according to claim 22 wherein the pH of the solution is from 0.5 to 6.5.

24. A process according to any one of claims 17 to 23 wherein the solution is seeded with previously formed particles of protein.

5 25. A fibril as claimed in any one of claims 1 to 16 whenever prepared by the process as claimed in any one of claims 17 to 24.

10 26. Use of a fibril according to any one of claims 1 to 16 or 25 in electronics or catalysis.

27. A fibril according to any one of claims 1 to 16 or 25 for use in the treatment of the human or animal body.

15

28. Use of a fibril according to any one of claims 1 to 16 or 25 in the manufacture of a medicament for use in the treatment of diabetes, blood clotting disorders, cancer and heart disease.

20

ABSTRACT

FIBRILS

An amyloid fibril substantially free of other protein.

THIS PAGE BLANK (USPTO)



Figure 1

THIS PAGE BLANK (USPTO)




Figure 2

THIS PAGE BLANK (USPTO)




Figure 3

THIS PAGE BLANK (USPTO)




Figure 4

THIS PAGE BLANK (USPTO)





Figure 5

THIS PAGE BLANK (USP 10,



Figure 6A



Figure 6B




Figure 6C

THIS PAGE BLANK (USPTO)




Figure 6D

PCT/48 99/03133

21-7-99

J. A. Kemp + Co.

THIS PAGE BLANK (USPTO)
